Ultimovacs Q2 2023 - Minor trial delays but investment case intact
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2023-08-23 08:29:00
Redeye comments on Ultimovacs’ Q2 2023 report, following a quarter in which the company’s share price took a hit due to inconclusive NIPU top-line data. We judge INITIUM top-line data in H1 2024e and more detailed NIPU data in Q4 2023e could provide critical catalysts for the share. We make minor changes in our valuation model.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/